Clinical Trials Directory

Trials / Completed

CompletedNCT01448213

Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)

Comparison Of Two Corticosteroid Dosing Regimens For Prevention Of Corneal Transplant Rejection Episodes After Descemet's Membrane Endothelial Keratoplasty

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
264 (actual)
Sponsor
Price Vision Group · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare two different commonly used steroid dosing regimens after Descemet's membrane endothelial keratoplasty (DMEK) transplant surgery. The investigators hope to determine if one is more effective at preventing rejection or if both are equally effective.

Detailed description

Graft rejection is one of the leading causes of cornea transplant failure. To help prevent rejection, corticosteroid eye drops are used after transplant surgery. The steroid eye drop dosing regimen varies from surgeon to surgeon, because no studies have been done to determine the optimum dosing regimen.

Conditions

Interventions

TypeNameDescription
DRUGPrednisolone acetateSubjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
DRUGFluorometholoneSubjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.

Timeline

Start date
2011-10-01
Primary completion
2014-01-01
Completion
2014-01-01
First posted
2011-10-07
Last updated
2014-09-03
Results posted
2014-08-25

Locations

2 sites across 2 countries: United States, Germany

Source: ClinicalTrials.gov record NCT01448213. Inclusion in this directory is not an endorsement.